DK3864009T3 - Tyk2-kinasehæmmere - Google Patents

Tyk2-kinasehæmmere Download PDF

Info

Publication number
DK3864009T3
DK3864009T3 DK19794095.0T DK19794095T DK3864009T3 DK 3864009 T3 DK3864009 T3 DK 3864009T3 DK 19794095 T DK19794095 T DK 19794095T DK 3864009 T3 DK3864009 T3 DK 3864009T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
tyk2 kinase
tyk2
inhibitors
kinase
Prior art date
Application number
DK19794095.0T
Other languages
Danish (da)
English (en)
Inventor
John Charles Reader
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Application granted granted Critical
Publication of DK3864009T3 publication Critical patent/DK3864009T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19794095.0T 2018-10-08 2019-10-07 Tyk2-kinasehæmmere DK3864009T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds
PCT/EP2019/077118 WO2020074461A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors

Publications (1)

Publication Number Publication Date
DK3864009T3 true DK3864009T3 (da) 2025-03-17

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19794095.0T DK3864009T3 (da) 2018-10-08 2019-10-07 Tyk2-kinasehæmmere

Country Status (18)

Country Link
US (1) US12187716B2 (enExample)
EP (1) EP3864009B1 (enExample)
JP (1) JP7383030B2 (enExample)
KR (1) KR102844196B1 (enExample)
CN (1) CN113056456B (enExample)
AU (1) AU2019359320B2 (enExample)
BR (1) BR112021006424A2 (enExample)
CA (1) CA3111049A1 (enExample)
DK (1) DK3864009T3 (enExample)
ES (1) ES3021420T3 (enExample)
FI (1) FI3864009T3 (enExample)
GB (1) GB201816369D0 (enExample)
IL (1) IL281599B2 (enExample)
MX (1) MX2021003929A (enExample)
PL (1) PL3864009T3 (enExample)
PT (1) PT3864009T (enExample)
SG (1) SG11202102490TA (enExample)
WO (1) WO2020074461A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
MXPA03003868A (es) 2000-10-30 2003-07-28 Janssen Pharmaceutica Nv Inhibidores de tripeptidil peptidasa.
EP1554269A1 (en) 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
EP1932833B1 (en) 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
ATE480525T1 (de) 2006-05-12 2010-09-15 Ab Science Neues verfahren zur synthese von 2- aminooxazolverbindungen
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2166846B1 (en) 2007-06-20 2012-10-17 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CA2730010A1 (en) 2008-07-09 2010-01-14 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
JP2013522267A (ja) 2010-03-17 2013-06-13 エフ.ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2013055645A1 (en) 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
DK2634185T3 (en) * 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
AU2013341186B2 (en) 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CN105793245B (zh) * 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
JP6310767B2 (ja) 2014-05-13 2018-04-11 日本電子株式会社 自動分析装置及びノズル洗浄方法
NO2721710T3 (enExample) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Also Published As

Publication number Publication date
ES3021420T3 (en) 2025-05-26
CA3111049A1 (en) 2020-04-16
MX2021003929A (es) 2021-06-04
BR112021006424A2 (pt) 2021-07-06
GB201816369D0 (en) 2018-11-28
EP3864009B1 (en) 2025-02-19
CN113056456B (zh) 2023-06-13
PL3864009T3 (pl) 2025-04-22
CN113056456A (zh) 2021-06-29
FI3864009T3 (fi) 2025-03-24
KR102844196B1 (ko) 2025-08-07
US20210387981A1 (en) 2021-12-16
KR20210076036A (ko) 2021-06-23
US12187716B2 (en) 2025-01-07
JP7383030B2 (ja) 2023-11-17
PT3864009T (pt) 2025-04-23
IL281599B1 (en) 2024-06-01
WO2020074461A1 (en) 2020-04-16
SG11202102490TA (en) 2021-04-29
IL281599A (en) 2021-05-31
JP2022514799A (ja) 2022-02-15
EP3864009A1 (en) 2021-08-18
IL281599B2 (en) 2024-10-01
AU2019359320A1 (en) 2021-03-18
AU2019359320B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
DK3999506T3 (da) Parp1-hæmmere
IL290779A (en) Heterocyclic rip1 kinase inhibitors
IL280593A (en) Pyrrolopyrimidine itk inhibitors
MA54550A (fr) Inhibiteurs de kif18a
IL282090A (en) Tyk2 inhibitors and uses thereof
EP4007756C0 (en) KIF18A INHIBITORS
DK3788040T3 (da) Pyridazinoner som parp7-inhibitorer
EP4007753C0 (en) Kif18a inhibitors
EP3801503A4 (en) INHIBITORS OF SARM1
EP3804707A4 (en) KINASE INHIBITOR
HUE057801T2 (hu) Aminotriazolopiridinek mint kináz inhibitorok
EP3902805A4 (en) CYCLINE-DEPENDENT KINASE INHIBITORS
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
DK3303334T3 (da) Tyrosinkinasehæmmere
MA52813A (fr) Inhibiteurs de sarm1
MA52809A (fr) Inhibiteurs de sarm1
HRP20260058T1 (hr) Dozni oblici za tyk2 inhibitore
HUE058292T2 (hu) Aminoimidazopiridazinok mint kináz inhibitorok
DK3783000T3 (da) Makrocyklisk kinasehæmmer
EP3817736A4 (en) PIKFYVE INHIBITORS
EP3927700A4 (en) KINAS INHIBITORS
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
DK3956322T3 (da) Jak1-selektiv kinaseinhibitor
EP3849985A4 (en) ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS